TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17341558

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (3 months of randomized and controlled physical activity-based lifestyle intervention)
Number of subjects: 21
Study: 15562016

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12476058

Group type: EXPERIMENTAL
Intervention: Teaching intervention (peer-developed diabetes management presentation)
Number of subjects: 72
Study: 9803586

Group type: EXPERIMENTAL
Intervention: AIK-C measles vaccine (4.0 log10pfu) administered at 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schwarz vaccine (3.7 log10pfu) given at 9 months
Number of subjects: 0
Study: 7633972

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg bd
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study: 2378442

Group type: EXPERIMENTAL
Intervention: Pharmalagen (n = 10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alavac (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (untreated; n = 6)
Number of subjects: 21
Study: 370940

Group type: EXPERIMENTAL
Intervention: Involved field radiation during induction in poor prognosis patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cranial irradiation plus intrathecal methotrexate during early remission
Number of subjects: 0
Study: 31470454

Group type: COMPARATOR
Intervention: Cefazolin alone (C)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cefazolin and vancomycin (CV)
Number of subjects: 3
Study: 31010516

Group type: EXPERIMENTAL
Intervention: Endovascular therapy by vascular surgery
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Endovascular therapy by interventional cardiology
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Endovascular therapy by interventional radiology
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Endovascular therapy by other specialties
Number of subjects: 865
Study: 28183564

Group type: EXPERIMENTAL
Intervention: Tramadol+paracetamol (Zaldiar; 325 mg paracetamol, 37.5 mg tramadol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25867186

Group type: EXPERIMENTAL
Intervention: Ganzfeld stimulation (visual deprivation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sleep (visual deprivation)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Free viewing (control)
Number of subjects: 35
Study: 23708155

Group type: EXPERIMENTAL
Intervention: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial injection of 1 × 10(5) autologous CD34(+) cells/kg
Number of subjects: 444

Group type: COMPARATOR
Intervention: G‐CSF‐mediated stem cell mobilization, apheresis, and intramyocardial placebo injection
Number of subjects: 444

Group type: COMPARATOR
Intervention: Open‐label standard of care
Number of subjects: 444
Study: 22251768

Group type: EXPERIMENTAL
Intervention: Pedometer intervention with a goal of 10,000 steps/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 19642771

Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway (FLMA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Endotracheal intubation (RAE group)
Number of subjects: 66
Study: 17381903

Group type: EXPERIMENTAL
Intervention: Food-frequency questionnaire (FFQ)
Number of subjects: 238

Group type: COMPARATOR
Intervention: 24-hour dietary recalls (24HDRs)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: FFQ
Number of subjects: 238
Study: 15272091

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 2481
Study: 11401931

Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein IIb/IIIa inhibitor (12 patients, 86%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (5 patients without CK‐MB elevation)
Number of subjects: 14
Study: 9040650

Group type: EXPERIMENTAL
Intervention: High-dose immunoglobulins (IVIg)
Number of subjects: 0
Study: 7510155

Group type: EXPERIMENTAL
Intervention: Proximal tubular parameters (alpha 1-microglobulin, N-acetyl-beta-D-glucosaminidase)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Distal tubular parameter (Tamm-Horsfall protein)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Albumin excretion (marker of glomerulum)
Number of subjects: 62
Study: 3301478

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31326395

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 29972987

Group type: EXPERIMENTAL
Intervention: Extraction group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-extraction group
Number of subjects: 48
Study: 26814319

Group type: EXPERIMENTAL
Intervention: RelyX U100 (self-adhesive resin cement)
Number of subjects: 10

Group type: COMPARATOR
Intervention: RelyX ARC (conventional resin cement)
Number of subjects: 10
Study: 25907772

Group type: EXPERIMENTAL
Intervention: DL-PICC (4.5-French, 60-cm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: DL-CICC (16-gauge, 30-cm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both DL-PICC and DL-CICC
Number of subjects: 40
Study: 23699984

Group type: EXPERIMENTAL
Intervention: Sunscreen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physical barrier
Number of subjects: 20
Study: 20876343

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (≤ 100 mmol/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-sodium diet (≥ 200 mmol/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily with low-sodium diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aliskiren 300 mg once daily with high-sodium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 0
Study: 15937679

Group type: EXPERIMENTAL
Intervention: Triiodothyronine treatment (1 microg/kg IV bolus followed by 0.06 microg/kg/hr continuous perfusion)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard support treatment (0.9% ClNa delivered over 270 min)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Triiodothyronine treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard support treatment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Triiodothyronine treatment and Standard support treatment
Number of subjects: 52
Study: 12797455

Group type: EXPERIMENTAL
Intervention: Homozygous 677 TT genotype
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Maternal vitamin use (no folic acid vitamins)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Maternal vitamin use (no folic acid vitamins) in high level SB defects
Number of subjects: 405
Study: 11064609

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8636743

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (100 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Low-dose cisplatin (50 mg/m2) plus epidoxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (100 mg/m2)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Low-dose cisplatin (50 mg/m2)
Number of subjects: 145
Study: 1731134

Group type: EXPERIMENTAL
Intervention: DTP mixed in the same syringe as PRP-T (group 1)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: DTP and PRP-T given at separate injection sites (group 2)
Number of subjects: 222

Group type: COMPARATOR
Intervention: DTP without PRP-T (group 3)
Number of subjects: 222
Study: 6147691

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: No prophylactic chemotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prophylactic chemotherapy
Number of subjects: 100
Study: 31612533

Group type: EXPERIMENTAL
Intervention: Behavioral-educational intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 51
Study: 30218385

Group type: EXPERIMENTAL
Intervention: vHIT (video head impulse test)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (healthy men without hearing loss)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Noise exposure hearing loss group
Number of subjects: 36
Study: 27622544

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25008473

Group type: EXPERIMENTAL
Intervention: 2 servings of pistachios per day (2PD; 34% TF)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inclusion of pistachios
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control diet (25% TF)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 serving of pistachios per day (1PD; 30% TF)
Number of subjects: 28
Study: 22326507

Group type: EXPERIMENTAL
Intervention: Smell of baked cookies present
Number of subjects: 109

Group type: COMPARATOR
Intervention: No-smell present
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Short-term cue exposure
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Long-term cue exposure
Number of subjects: 109
Study: 21291037

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 21
Study: 18565634

Group type: EXPERIMENTAL
Intervention: Marlboro Lights (ML)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Marlboro Ultra Lights (MUL)
Number of subjects: 225

Group type: COMPARATOR
Intervention: MFF (Control)
Number of subjects: 225
Study: 15820805

Group type: COMPARATOR
Intervention: Serial transvaginal power Doppler ultrasound assessments throughout the follicular phase of ovarian stimulation.
Number of subjects: 34
Study: 12588385

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg three times a day for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo tablet three times a day for 2 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Preference expressed by patients
Number of subjects: 24
Study: 11092773

Group type: EXPERIMENTAL
Intervention: Intravenous sedation with midazolam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local anaesthesia only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local anaesthesia and intravenous sedation
Number of subjects: 60
Study: 8776215

Group type: EXPERIMENTAL
Intervention: E + P trial (exercise + postprandial)
Number of subjects: 12

Group type: COMPARATOR
Intervention: P trial (postprandial)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: During exercise
Number of subjects: 12
Study: 1629747

Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Gentamicin plus piperacillin
Number of subjects: 61
Study: 6835891

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 100
Study: 30132008

Group type: EXPERIMENTAL
Intervention: Workplace neck-specific exercises
Number of subjects: 763
Study: 29930161

Group type: EXPERIMENTAL
Intervention: Ramipril (6 mg/m2 per day)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Ramipril therapy with proteinuria reduction <30%
Number of subjects: 280

Group type: COMPARATOR
Intervention: Ramipril therapy with proteinuria reduction 30%-60%
Number of subjects: 280

Group type: COMPARATOR
Intervention: Ramipril therapy with proteinuria reduction >60%
Number of subjects: 280
Study: 26702872

Group type: EXPERIMENTAL
Intervention: Surgery (S)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Surgery + Radiotherapy (S + RT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients >15 years
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients <15 years
Number of subjects: 51
Study: 25416925

Group type: EXPERIMENTAL
Intervention: Resveratrol plus carboxymethyl‐β‐glucan
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline isotonic solution
Number of subjects: 82
Study: 22178850

Group type: COMPARATOR
Intervention: No supplemental vitamin A or D (NAND)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 3,750 IU vitamin A/kg dietary DM with no supplemental vitamin D (SAND)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: No supplemental vitamin A and 1,860 IU vitamin D/kg dietary DM (NASD)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 3,750 IU and 1,860 IU vitamin A and D/kg dietary DM (SASD)
Number of subjects: 168

Group type: COMPARATOR
Intervention: No supplemental vitamin A (NAND and NASD combined)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Diet without supplemental vitamin A
Number of subjects: 168
Study: 20951555

Group type: EXPERIMENTAL
Intervention: Vigabatrin for ≥ 6 months (Group I)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Vigabatrin discontinued for ≥ 6 months (Group II)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Naïve to vigabatrin (Group III)
Number of subjects: 258
Study: 17386354

Group type: EXPERIMENTAL
Intervention: zofenopril (15 to 30 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: ramipril (2.5 to 5 mg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg/d)
Number of subjects: 45
Study: 10691158

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 1 mg plus sulphonylurea
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg plus sulphonylurea
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo plus sulphonylurea
Number of subjects: 574
Study: 9174875

Group type: EXPERIMENTAL
Intervention: Sauna bathing session (heat exposure: 76-87 degrees C, relative humidity 27-33%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control session (room temperature: 23 degrees C)
Number of subjects: 8
Study: 8246029

Group type: EXPERIMENTAL
Intervention: ondansetron plus dexamethasone
Number of subjects: 287

Group type: COMPARATOR
Intervention: metoclopramide plus dexamethasone and diphenhydramine
Number of subjects: 287
Study: 3079939

Group type: EXPERIMENTAL
Intervention: 0.2 mg GTN spray
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.4 mg GTN spray
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.8 mg GTN spray
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual GTN
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study: 31714954

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole preventive therapy (CPT) continued
Number of subjects: 172

Group type: COMPARATOR
Intervention: Cotrimoxazole preventive therapy (CPT) discontinued (placebo)
Number of subjects: 172
Study: 28895673

Group type: EXPERIMENTAL
Intervention: Active IFC group (N=30)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham IFC group (N=30)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Comparison between active IFC and sham IFC groups
Number of subjects: 65
Study: 26740684

Group type: EXPERIMENTAL
Intervention: 10 g LNS/d
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: 20 g LNS/d
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: 40 g LNS/d
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: LNS intervention groups (10 g, 20 g, 40 g)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Non-LNS CFs
Number of subjects: 748
Study: 24890138

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 22709949

Group type: EXPERIMENTAL
Intervention: 23vPPS vaccine (Pneumovax(®))
Number of subjects: 340

Group type: COMPARATOR
Intervention: inactivated influenza vaccine (Fluarix(®))
Number of subjects: 340
Study: 20479459

Group type: EXPERIMENTAL
Intervention: Retropubic sling
Number of subjects: 597

Group type: COMPARATOR
Intervention: Transobturator sling
Number of subjects: 597
Study: 17460616

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 26
Study: 15866560

Group type: EXPERIMENTAL
Intervention: Orlistat plus CBTgsh (120 mg three times a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus CBTgsh
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 50
Study: 12570939

Group type: EXPERIMENTAL
Intervention: eptifibatide plus enoxaparin
Number of subjects: 261

Group type: COMPARATOR
Intervention: eptifibatide plus unfractionated heparin
Number of subjects: 261
Study: 10554416

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg/day for 2 weeks before surgery)
Number of subjects: 34
Study: 8908527

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol with 150 micrograms desogestrel
Number of subjects: 1633

Group type: COMPARATOR
Intervention: 20 micrograms ethinylestradiol with 150 micrograms desogestrel
Number of subjects: 1633
Study: 1858442

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1800-2400 mg per day for 3 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 17
Study: 30738380

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 454

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 454
Study: 28052714

Group type: EXPERIMENTAL
Intervention: Rectal ibuprofen
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 72
Study: 25884223

Group type: EXPERIMENTAL
Intervention: EMDR (seven weekly 90 minute sessions) + TAU
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 100
Study: 24229598

Group type: EXPERIMENTAL
Intervention: Probiotics (live combined bifidobacterium and lactobacillus tablets)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral immunoglobulin (anti‐rotavirus egg yolk immunoglobulin, IgY)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 150
Study: 21175873

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 21
Study: 19935591

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy (1 hour/day for multiple sessions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study: 18626265

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/d
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Olanzapine 40 mg/d
Number of subjects: 599

Group type: COMPARATOR
Intervention: Olanzapine (all doses)
Number of subjects: 599
Study: 16145844

Group type: EXPERIMENTAL
Intervention: Mineralized solvent‐dehydrated cancellous bone allograft
Number of subjects: 7

Group type: COMPARATOR
Intervention: Composite of DFDBA and deproteinized bovine bone xenograft (1:1)
Number of subjects: 7
Study: 12697078

Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 623

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam, 3.375 g every 6 hours
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Ertapenem for IAI
Number of subjects: 623

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam for IAI
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Ertapenem for SSSI
Number of subjects: 623

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam for SSSI
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Ertapenem for PI
Number of subjects: 623

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam for PI
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 623
Study: 10428144

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (without ketoconazole)
Number of subjects: 18
Study: 7675994

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0
Study: 2075623

Group type: EXPERIMENTAL
Intervention: Billings ovulation method
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Local mucus method
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Dorairaj modified mucus method
Number of subjects: 850
Study: 6110912

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (nasal prongs for at least 15 h daily, usually at 2 l/min)
Number of subjects: 87

Group type: COMPARATOR
Intervention: No oxygen (controls)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 87
Study: 30449116

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 90

Group type: COMPARATOR
Intervention: Onset formula (control group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Regular gluten consumption (control group 2)
Number of subjects: 90
Study: 28433339

Group type: EXPERIMENTAL
Intervention: Snare cannulation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Retrograde cannulation
Number of subjects: 101
Study: 25796338

Group type: EXPERIMENTAL
Intervention: Bivalent HPV‐16/18 vaccine
Number of subjects: 7466

Group type: COMPARATOR
Intervention: Control Hepatitis‐A vaccine
Number of subjects: 7466

Group type: COMPARATOR
Intervention: Unvaccinated control group (UCG)
Number of subjects: 7466
Study: 22878782

Group type: EXPERIMENTAL
Intervention: PE in a spread added into a liquid meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PE given 30 min after a liquid meal as 100-g yoghurt drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: No PE added (control)
Number of subjects: 12
Study: 21865332

Group type: EXPERIMENTAL
Intervention: Increased supplemental zinc
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 67
Study: 19490296

Group type: EXPERIMENTAL
Intervention: Internet education programme
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study: 16460492

Group type: EXPERIMENTAL
Intervention: Ribavirin and 6 MU interferon-alpha2b
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ribavirin and 10 MU interferon-alpha2b
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ribavirin and 6 MU interferon-alpha2b (group C)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ribavirin and 10 MU interferon-alpha2b (group D)
Number of subjects: 76